NGEN (NervGen Pharma) EBITDA Margin %: 0.00% (As of Mar. 2026)


NGEN NervGen Pharma Corp NGEN
22 GF Score
Price $1.87
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma EBITDA Margin %?

NervGen Pharma NGEN -1.06% 22 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, NervGen Pharma ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. NervGen Pharma's EBITDA for the three months ended in Mar. 2026 was $-5.49 Mil. NervGen Pharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, NervGen Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

NervGen Pharma  (NAS:NGEN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

NervGen Pharma EBITDA Margin % Related Terms

NervGen Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for NervGen Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma EBITDA Margin % Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

NervGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NGEN vs CNTN, ELTX, KROS: EBITDA Margin % Comparison

For the Biotechnology subindustry, NervGen Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NervGen Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's EBITDA Margin % falls into.


NGEN
22GF Score
NervGen Pharma Corp NGEN
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NervGen Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

NervGen Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-18.139/0
= %

NervGen Pharma's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-5.49/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
NervGen Pharma (NGEN) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NervGen Pharma and its competitors. According to the industry distribution chart, NervGen Pharma ranks #999999 out of 944 companies in the Biotechnology industry.
Is NervGen Pharma's EBITDA Margin % too high?
NervGen Pharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, NervGen Pharma ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's EBITDA Margin % compare to CNTN and ELTX?
According to the Biotechnology industry distribution chart, NervGen Pharma ranks #999999 out of 944 companies for EBITDA Margin %. This places NervGen Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NervGen Pharma and its competitors. NervGen Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NervGen Pharma Business Description

Other Exchanges 9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score

Get the complete analysis for NGEN

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.87
Price